Treatment of congestive heart failure. Has the time come for decreased complexity?

European Heart Journal

Volumn 20, Issue 12, 1999, Pages 867-871

  Ryden L ^a   Remme, W J ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

ACE inhibitors; Beta blockers; Congestive heart failure; Morbidity; Mortality; Pharmacological therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; METOPROLOL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MYOCARDIUM; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0032981453     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1393     Document Type: Review

References (22)

1. The Task Force of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J. 16:1995;741-751.
2. The Task Force of the European Society of Cardiology. Guidelines for the treatment of heart failure. Eur Heart J. 18:1997;736-753.
3. N Engl J Med. 316:1987;1429-1435.
4. The SOLVD Investigators. Effects on enalapril on mortality and the development of heart failure in asymtomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
5. Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbiede dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
6. N Engl J Med. 325:1991;293-302.
7. Packer M, Carver JR, Rodeheffer RJ. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
8. Feldman A, Young J, Bourge R. Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VEST). J Am Coll Card. 29(2 Suppl A):1997;64A.
9. Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
10. CIBIS Investigators and Committees. A randomised trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol study (CIBIS). Circulation. 90:1994;1765-1773.
11. Feurstein GZ, Schusterman NH, Ruffalo RR. Carvedilol update IV: prevention of oxidative stress, cardiac remodelling and progression of congestive heart failure. Drugs Today. 33:1997;453-457.
12. Packer M, Bristow MR, Cohn J. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
13. Australia/New Zealand Heart Failure Collaborative Group. Randomised placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 349:1996;375-380.
14. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 71:1994;584-587.
15. Packer M, Poole-Wilson P, Armstrong P. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic congestive heart failure: the assessment of treatment with lisinopril and survival study (ATLAS). Eur Heart J. 19:1998;905.
16. Bristow MR, Gilbert EM, Abraham WT. Carvedilol produces dose-related improvements in left ventricular failure. MOCHA Investigators. Circulation. 94:1996;2807-2816.
17. Sabbah HN, Shimoyama H, Kono T. Effects of long term monotherapy with enalapril, metoprolol and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 89:1994;2852-2859.
18. Doughty RN, Whally GA, Gamble G. Left ventricular remodelling in patients with congestive heart failure due to ischemic heart disease. J am Coll Card. 29:1997;1060-1066.
19. Lowes D, Gill EA, Rodriguez-Larrain J. Carvedilol is associated with a reversal of remodelling in chronic heart failure. Circulation. 94(8 Suppl 1):1996;I-407-A 2371.
20. Senior R, Basu S, Lahiri A. Carvedilol prevents remodelling and improves prognosis in patients with left ventricular dysfunction following acute myocardial infarction. J Am Coll Card. 27:1997;319A.
21. Gilbert EM, Colucci WS, Fowler WS. Carvedilol without ACE-inhibition in the treatment of patients with moderate to severe chronic heart failure. Circulation. 94 (Suppl):1996;I-663-A 3875.
22. Janson K, Karlberg KE, Nylander E. More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy. Eur Heart J. 18:1997;1115-1121.